Steve Schonfeld’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.95M | Sell |
13,005
-39,954
| -75% | -$7.11M | 0.01% | 872 |
|
|
2026
Q1 | $9.14M | Buy |
52,959
+2,077
| +4% | +$385K | 0.06% | 324 |
|
|
2025
Q4 | $10.1M | Buy |
50,882
+23,720
| +87% | +$4.3M | 0.05% | 343 |
|
|
2025
Q3 | $4.25M | Sell |
27,162
-36,425
| -57% | -$5.79M | 0.02% | 657 |
|
|
2025
Q2 | $9.65M | Buy |
63,587
+61,677
| +3,229% | +$8.22M | 0.07% | 350 |
|
|
2025
Q1 | $287K | Sell |
1,910
-2,053
| -52% | -$344K | ﹤0.01% | 1810 |
|
|
2024
Q4 | $732K | Buy |
3,963
+152
| +4% | +$29.3K | ﹤0.01% | 1255 |
|
|
2024
Q3 | $751K | Buy |
3,811
+1,669
| +78% | +$347K | 0.01% | 1261 |
|
|
2024
Q2 | $442K | Sell |
2,142
-61,403
| -97% | -$13.9M | ﹤0.01% | 1540 |
|
|
2024
Q1 | $17.2M | Buy |
+63,545
| New | +$15.2M | 0.11% | 210 |
|
|
2023
Q4 | – | Sell |
-12,004
| Closed | -$2.35M | – | 1914 |
|
|
2023
Q3 | $2.35M | Buy |
12,004
+8,285
| +223% | +$1.7M | 0.02% | 776 |
|
|
2023
Q2 | $782K | Buy |
+3,719
| New | +$740K | 0.01% | 1063 |
|
|
2022
Q1 | – | Sell |
-1,283
| Closed | -$483K | – | 2640 |
|
|
2021
Q4 | $483K | Buy |
+1,283
| New | +$498K | ﹤0.01% | 1284 |
|
|
2021
Q3 | – | Sell |
-871
| Closed | -$322K | – | 2203 |
|
|
2021
Q2 | $322K | Sell |
871
-5,223
| -86% | -$1.74M | ﹤0.01% | 1426 |
|
|
2021
Q1 | $1.77M | Buy |
6,094
+2,368
| +64% | +$658K | 0.02% | 705 |
|
|
2020
Q4 | $931K | Sell |
3,726
-3,525
| -49% | -$840K | 0.01% | 841 |
|
|
2020
Q3 | $1.64M | Buy |
+7,251
| New | +$1.5M | 0.03% | 566 |
|
|
2020
Q2 | – | Sell |
-8,022
| Closed | -$1.01M | – | 1286 |
|
|
2020
Q1 | $1.01M | Buy |
8,022
+6,370
| +386% | +$955K | 0.06% | 366 |
|
|
2019
Q4 | $252K | Sell |
1,652
-3,848
| -70% | -$533K | 0.01% | 1061 |
|
|
2019
Q3 | $728K | Sell |
5,500
-6,200
| -53% | -$831K | 0.02% | 550 |
|
|
2019
Q2 | $1.66M | Sell |
11,700
-27,108
| -70% | -$3.68M | 0.06% | 330 |
|
|
2019
Q1 | $5.64M | Buy |
38,808
+6,065
| +19% | +$797K | 0.2% | 139 |
|
|
2018
Q4 | $3.71M | Buy |
32,743
+11,491
| +54% | +$1.44M | 0.14% | 199 |
|
|
2018
Q3 | $2.86M | Sell |
21,252
-8,748
| -29% | -$1.08M | 0.13% | 220 |
|
|
2018
Q2 | $3.37M | Buy |
30,000
+5,000
| +20% | +$541K | 0.18% | 188 |
|
|
2018
Q1 | $2.67M | Sell |
25,000
-25,125
| -50% | -$2.71M | 0.2% | 148 |
|
|
2017
Q4 | $5.49M | Buy |
50,125
+125
| +0.3% | +$13.6K | 0.45% | 59 |
|
|
2017
Q3 | $5.4M | Sell |
50,000
-5,747
| -10% | -$590K | 0.49% | 59 |
|
|
2017
Q2 | $5.64M | Sell |
55,747
-6,088
| -10% | -$560K | 0.58% | 34 |
|
|
2017
Q1 | $5.56M | Buy |
+61,835
| New | +$5.25M | 0.56% | 35 |
|
Other funds holding CRL
AI
Steve Schonfeld's CRL Position: Q2 2026 in Review
Steve Schonfeld reduced its Charles River Laboratories (CRL) stake by 75% in Q2 2026, selling an estimated $7.11M and leaving 13,005 shares worth $2.95M. The position accounts for 0.01% of the portfolio, ranked #872.
Steve Schonfeld first reported a position in CRL in Q1 2017 and has held it in 30 quarters since. The position peaked at $17.2M in Q1 2024. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Steve Schonfeld held 13,005 shares of Charles River Laboratories worth $2.95M as of Q2 2026.
- Steve Schonfeld sold 39,954 Charles River Laboratories shares in Q2 2026, an estimated $7.11M.
- Charles River Laboratories made up 0.01% of Steve Schonfeld's portfolio in Q2 2026, its #872 holding.
- Steve Schonfeld first reported a position in Charles River Laboratories in Q1 2017 and has held it in 30 quarters since.
- Steve Schonfeld's Charles River Laboratories position peaked at $17.2M in Q1 2024.
- 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.